Blueshift Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Blueshift Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$351K	Buy	4,433 +1,656	+60%	+$125K	0.08%	326
2026 Q1	$209K	Sell	2,777 -7,666	-73%	-$605K	0.06%	439
2025 Q4	$826K	Sell	10,443 -1,017	-9%	-$76.6K	0.24%	109
2025 Q3	$750K	Buy	+11,460	New	+$560K	0.23%	116
2019 Q3	–	Sell	-3,423	Closed	-$220K	–	834
2019 Q2	$220K	Buy	+3,423	New	+$242K	0.03%	631

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Blueshift Asset Management's IONS Position: Q2 2026 in Review

Blueshift Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 60% in Q2 2026, buying an estimated $125K and bringing the position to 4,433 shares worth $351K. The position accounts for 0.08% of the portfolio, ranked #326.

Blueshift Asset Management first reported a position in IONS in Q2 2019 and has held it in 5 quarters since. The position peaked at $826K in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Blueshift Asset Management held 4,433 shares of Ionis Pharmaceuticals worth $351K as of Q2 2026.
Blueshift Asset Management bought 1,656 Ionis Pharmaceuticals shares in Q2 2026, an estimated $125K.
Ionis Pharmaceuticals made up 0.08% of Blueshift Asset Management's portfolio in Q2 2026, its #326 holding.
Blueshift Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2019 and has held it in 5 quarters since.
Blueshift Asset Management's Ionis Pharmaceuticals position peaked at $826K in Q4 2025.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.